GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 Proprietary Forzet formulation provides pharmacists ...

ACC/AHA guidance also gives boost to non-cholesterol tests ...

Raffle at Upcoming Islanders Game Will Support Eosinophilic Disease Research ATLANTA, GA, UNITED STATES, March 6, ...

Today, almost a third of U.S. adults are overweight and 43% have obesity. Behaviors that are likely to influence weight may ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are a class of Type 2 diabetes drugs that improves blood sugar and may also lead to weight loss. These drugs — including ...

Not all saturated fats are identical or affect the body in the same way. Learn about the different kinds and their impacts on ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for ...

While GLP-1 drugs can be effective for weight loss, they are not necessarily a permanent solution. Therefore, the duration of treatment can vary.

A new petition from MAHA activists call for an end to "forever wars" ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the award of an up ...

Produce prescriptions and hospital food programs are expanding fast. But the real test isn’t medical—it’s financial.

Ozempic is intended to help people with diabetes manage blood sugar. A dietitian breaks down exactly what Ozempic is, and if ...